Market Cap: $11.79B
MI
Madrigal Pharmaceuticals, Inc.
MDGL
NASDAQ (NASDAQ Global Select)USD
Market Cap: $11.79B
Madrigal Pharmaceuticals (Ticker: MDGL) is currently receiving renewed attention due to the presentation of promising data regarding its drug Rezdiffra at the EASL Congress 2026. This presentation sho…
Madrigal Pharmaceuticals (Ticker: MDGL) recently unveils compelling data on its drug Rezdiffra, aimed at treating liver diseases, which is generating significant interest in the pharmaceutical communi…
Madrigal Pharmaceuticals Faces Mixed Analyst Sentiment Amid Uncertainty Madrigal Pharmaceuticals currently captures attention with its dual narrative of optimism and skepticism emerging from recent an…
Madrigal Pharmaceuticals Faces Divergent Analyst Sentiment Amid Regulatory Uncertainty Madrigal Pharmaceuticals stands at a crossroads as it navigates a complex landscape of investor expectations and…
I can’t produce the requested summary because the text to be summarized isn’t included. You posted a note asking for the article to be pasted — I need that text (or a link) to make a faithful Reuters‑…
I can’t summarise because you didn’t paste the article text or a link. Please either paste the article you want summarised (or a link to it), or tell me you want me to use public news up to my knowled…
Madrigal secures siRNA platform to broaden MASH treatment strategy Strategic licensing widens Madrigal's liver-directed arsenal Madrigal Pharmaceuticals is gaining exclusive worldwide rights to six pr…
Madrigal secures GalSTAR siRNA suite to broaden MASH portfolio Madrigal Pharmaceuticals is obtaining exclusive worldwide rights to six pre‑clinical small interfering RNA (siRNA) programs from Suzhou R…
Madrigal wins exclusive global license to Ribo’s liver‑targeted siRNA assets for MASH Madrigal Pharmaceuticals is securing exclusive worldwide rights to six pre‑clinical small interfering RNA (siRNA)…
Madrigal Pharmaceuticals Gears Up for Key Earnings Report Amid Rising Demand for Innovative Therapies As Madrigal Pharmaceuticals prepares to unveil its quarterly earnings report on November 4, 2025,…
Madrigal Pharmaceuticals Gears Up for Key Earnings Report Amid NASH Treatment Progress Madrigal Pharmaceuticals is on the brink of releasing its quarterly earnings report on November 4, 2025, a pivota…
Madrigal Pharmaceuticals Gears Up for Key Earnings Report Amid Promising Drug Development Madrigal Pharmaceuticals is set to release its quarterly earnings report on November 4, 2025, a development ge…
Madrigal Pharmaceuticals: Navigating a Complex Landscape of Analyst Opinions Madrigal Pharmaceuticals (MDGL) is currently positioned at a critical juncture in its development journey, attracting a wid…
Madrigal Pharmaceuticals: Navigating Diverse Analyst Sentiments in Drug Development Madrigal Pharmaceuticals is currently experiencing a wave of analyst evaluations that illustrate the complexities of…
Madrigal Pharmaceuticals: Navigating a Transformative Landscape in Biopharmaceuticals Madrigal Pharmaceuticals is currently positioned in a dynamic environment within the biopharmaceutical sector, mar…
Madrigal Pharmaceuticals Faces Analyst Divergence Amid Pipeline Development Madrigal Pharmaceuticals finds itself at a pivotal moment, as four analysts present a spectrum of ratings that reflect both…
New FDA Approval Expands Treatment Options for Liver Disease The U.S. Food and Drug Administration (FDA) recently grants approval for Novo Nordisk A/S's Wegovy (semaglutide 2.4 mg) to treat noncirrhot…
Wegovy's Expanded Role: A Game-Changer in Liver Disease Management In a significant advancement for metabolic disorder treatment, the U.S. Food and Drug Administration (FDA) grants approval for Novo N…
Madrigal Pharmaceuticals: Navigating New Frontiers in Liver Disease Treatment Madrigal Pharmaceuticals continues to position itself as a key player in the field of liver disease management, particular…
Madrigal Pharmaceuticals Advances Liver Health with Positive CHMP Opinion Madrigal Pharmaceuticals, Inc. receives a significant endorsement from the Committee for Medicinal Products for Human Use (CHM…